The Abu Dhabi Stem Cells Centre (ADSCC) has signed an agreement with Israeli research company Pluristem Therapeutics to study and develop regenerative medicines, including those that can be used to fight the Covid-19 pandemic. Under the accord, the companies will exchange results, share samples and transfer knowledge related to cell therapies for a broad range of medical conditions including the coronavirus, state news agency Wam reported on Monday. "Pluristem have proven themselves to be formidable players in the stem cells field and we look forward to working together with great excitement," Yendry Ventura, general manager of ADSCC, said. The pact was signed by the representatives from both companies during a ceremony held through videoconference on Monday. Regenerative medicine develops products to replace or regenerate human cells, tissues and organs to restore normal functions. It allows scientists to grow tissue under controlled conditions in a laboratory and safely implant it in the human body when it is unable to heal itself. Founded in March last year, ADSCC has been a driving force behind medical research in the country, including playing a key role in the ongoing fight against the Covid-19. In June, it announced the results of a trial of its treatment for Covid-19 patients, branded UAECell19. The centre's work has involved taking stem cells from a patient’s blood and returning them, via a nebuliser, as a fine mist to the lungs. This helps to regenerate lung cells and improve the body's immune response by preventing an overreaction to the infection that can damage healthy cells. “We see life science and regenerative medicine as a bridge for building peace, prosperity and wellbeing in our region and for the entire world,” Yaki Yanai, chief executive and president of Pluristem, said.